Our Core Technologies
Our Core Technologies result from years of both private and university research and development by pioneers in the field of biotechnology, in collaboration with medical practitioners within various fields of medicine throughout the world.
PERIPHERAL BLOOD DERIVED PLURIPOTENT STEM CELLS
Our PBD-PSC Technology is based on discoveries involving a distinct population of pluripotent stem cells, initially isolated from adipose-tissue, but found in abundance in bone marrow, from where they originate, and present in peripheral blood as well as other body fluids. These cells express a unique marker that can be used to select them for both diagnostic and therapeutic procedures utilizing a proprietary antibody on its own or in combination with existing commercially available antibodies. These cells are in abundance in peripheral blood and in reproductive tissue secretions and dissipate in number and function in humans as they age. The Company’s scientists have determined that these cells play a large role in future stem cell based diagnostic and therapeutic applications in both humans and animals. Furthermore, unlike adipose tissue derived cells, peripheral blood derived pluripotent stem cells can be taken from healthy donors.
The PBD-PSC Technology relies upon a proprietary antibody manufactured for the unique detection and isolation of Peripheral Blood Derived Parathyroid Hormone Receptor Positive Pluripotent Stem Cell. The Company has developed two processes for detection and isolation of these cells including: (i) a uniquely designed cell isolation and processing device offered in kit form, employing a simple medical procedure commonly used in Platelet Rich Plasma (“PRP”) for clinical use by treating physicians and (ii) a proprietary procedure in which the Company’s Authorized Laboratories will process the blood drawn from a patient, submitted by a medical clinic, and deliver to the medical clinic the parathyroid hormone receptor positive peripheral blood derived pluripotent stem cells for injection into the patient by the treating physician.
Patent’s regarding the various applications of the PBD-PSC Technology have been filed, and the proprietary antibody, necessary for the positive selection of the parathyroid hormone receptor positive peripheral blood derived pluripotent stem cells is a unique component protected as a trade secret.
Current research has shown that therapy applying the PBD-PSC Technology is effective in improving fertility and augmenting IVF success by: (a) increasing egg health and overall ovarian function of an aged female and (b) increasing the thickness and improving the receptivity of the lining of the uterine endometrium tissue in women experiencing infertility, a known cause of infertility. Current research has also shown that the PBD-PSC Technology can be utilized to render red blood cells and to produce hair follicles, in vitro.
Further, based on current results from research and clinical testing, Our scientists believe that, with further clinical trials, the applications of the PBD-PSC Technology could be shown useful in replacing bone marrow in post-cancer treatment, and in the treatment of a wide range of degenerative diseases in both humans and animals including, but not limited to: diabetes, osteoarthritis, osteoporosis and Alzheimer’s disease, to name a few, as well as regenerative applications associated with aging.
“AD-813 PEPTIDE TECHNOLOGY”
Our Ad-813 Peptide Technology is based on discovery of the Ad-813 peptide, discovered through the course of work in the area of adipose derived stem cells, during which it was noted that the core therapeutic mechanism of action of these adipose-derived stem cells was not their ability to differentiate into the target tissue, but their ability to secrete a plethora of growth factors to instigate the healing process. This explained the drop in insulin resistance in Type2 Diabetes patients and the positive multi-faceted effects observed in these patients.
A large, two year proteomic study was then conducted with the Australian Proteome Facility and over 400 proteins and growth factors were discovered to be secreted by these adipose-derived stem cells. One of the proteins which was discovered in abundance was Thymosin β4. It was first discovered in the 1970’s during research on the physiological and immunoregulatory function of the thymus gland. It is ubiquitous in all animals and hence treatments derived from it also have applications in veterinary medicine.
It has previously been known that Thymosin β4 had useful attributes in the areas of wound healing, pain suppression and the stimulation of stem cells. Researchers have been able to demonstrate that an active segment of the Thymosin β4 protein, the peptide termed Ad 813, has the majority of these attributes. Furthermore, the Ad-813 peptide can be synthesized in the laboratory and accordingly does not require extraction procedures from a human body. This opens up the possibility of mass treatment with no risk of tissue rejection, and mass laboratory production. Sample batches were initially made by Auspep Pty. Ltd. in Australia, and large scale batches have already been produced by G.L. Biochem, based in Shanghai.
The Ad-813 peptide has been registered as a topical cosmetic (non-medical) for applications such as anti-aging are close to market and will continue to be developed within Tithon.
ADI-LIGHT-2 CELL PHOTO-ACTIVATOR
“CELL PHOTOACTIVATION TECHNOLOGY”
We received a worldwide exclusive sub-license to market, sell, distribute and sublicense, within the animal “field of use”, therapeutic applications of the Adistem products and intellectual property covered under PCT Patent, PCT/CN2010/072041, which includes all of the Adistem kits and materials utilized in connection with the removal, separation, activation and reinjection of stems cells derived from the patient’s own adipose (fat) tissue or removal, separation, activation and reinjection of platelet rich plasma, in each case activated through exposure to a proprietary photo-activation device, resulting in the reintroduction of activated multipotent stem cells or platelet rich plasma into the patient’s body. Simultaneous therewith, We received an assignment of all of Adistem’s rights and duties under the MediVet EMDA.
Adi-Light 2 Use to Activate Stem Cells
Since 2008, Photoactivation Technology has been used for activating adipose-derived stem cells (ASCs) for therapeutic and regenerative application. ASCs lie dormant within adipose tissue and require photo-activation to ‘awaken’ and come into full functionality and begin self-renewal by cell division and formation of other cell types through differentiation and transdifferentiation. The very high volume of ASCs in adipose tissue means there is no need to culture these cells in a laboratory for days to achieve a “therapeutic threshold”, i.e., therapeutic benefit. Harvesting ASCs is done through liposuction under local anesthesia. It is a single procedure in a sterile setting. Prior to photo-activation, stem cell treatments require the use of a proprietary “Cell Extraction Medium” to isolate stem cells from the fat.
Adi-Light 2 Use in PRP Treatments
AdiStem’s proprietary Photoactivation Technology is being used increasingly in Platelet Rich Plasma (PRP) preparations for Osteoarthritis, Degenerative Knees, Muscle Tears, Tendon Injuries, Joint Pain and Ligament Injuries.
Ten minutes exposure of PRP to AdiLight-2 photo-activation, prior to injecting, has been found to significantly reduce inflammation and accelerate healing through enhancing growth factors and increasing Interleukin I – Receptor Antagonist. Patients begin to feel relief from pain within a couple of days – instead of weeks or months.
“ANTIGEN-SPECIFIC IMMUNOTHERAPY TECHNOLOGY”
Our Antigen-Specific Immunotherapy Technology employs a process developed by Paspa Pharmaceuticals Pty. Ltd., in which various proprietary immortal human tissue cell lines (“Proprietary Tissue Cell Lines”) are processed using a proprietary method, also developed and tested by Paspa, in which the live cells of a particular tissue line are lysed through use of ultrasound, thereby destroying the living cell and rendering the cell’s membrane fragments, while also sterilizing the liquid containing the fragmented cells. The rendered cell membranes are then potentized” through homeopathic succession/dilution techniques by a licensed FDA-cGMP approved manufacturing facility, for delivery, as what is known as a “sarcode” in “isopathy or “iso-organotherapy,” a subset of homeopathy, and sold as an FDA registered OTC drug.
Paspa, through both laboratory and clinical testing, has demonstrated that these various Proprietary Tissue Cell Lines, as processed into an isopathic sarcode liquid or spray, when administered over a recommended period of time, evidence a dampening down of the body’s own antibody aggression against the body’s own tissues targeted by the specific Proprietary Tissue Cell Line rendered into an isopathic sarcode, thereby also converting the body’s aggressive immune response cells, attacking the bodies self-tissue, into cells capable of protecting against disease (i.e. immune tolerance).
LYMPHOCYTE MEMBRANE AND HLA1113AG
Our LMIT/HLA131115AG Technologies are based on a recently developed process for increasing female immune tolerance to paternal antigens through either
- subcutaneous injections of paternal antigens derived from the male partner’s or donor’s lymphocyte membranes, or, alternatively
- oral application of a recently discovered human lymphocyte antigen referred to as HLA131115Ag (“HLA131115Ag”), initially discovered to be present in a male white blood T cell line that the has shown in clinical testing to serve as a universal paternal antigen for use as: (i) a diagnostic marker for testing immune response to HLA131115Ag paternal antigen by women considering becoming pregnant and those experiencing Recurrent Pregnancy Loss (“RPL”); and (ii) a therapeutic trans-dermally applied penetrant solution to slowly introduce HLA131115Ag to increase maternal tolerance to paternal antigen, for women considering becoming pregnant and those experiencing RPL.
The diagnostic and therapeutic technologies are based on research conducted by Paspa Pharmaceuticals Pty. Ltd. Such research indicated that females who have reoccurring pregnancy loss have marked changes in IgM and IgG antibodies to HLA131115Ag, as compared to women experiencing successful pregnancy. Further testing confirmed that the same protein, when delivered trans-dermally to women along with a simple lymphocyte immunotherapy from the male partner such as available through the LMIT therapy, increased IVF pregnancy outcome to 60%.
Our Alginate Technology is based on discovery of a method for cross linking sodium alginate, resulting in a superior bond to that available using the current method of utilizing calcium for cross-linking alginate. Testing has shown that not only was a superior bond produced, but the resulting material possessed antimicrobials qualities, resulting in both non-medical applications and, due to its unique properties, medical applications.
These characteristics suggest that this method could be commercialized for: (i) non-medical uses in the food industry, the textile and paper industries, the welding and molding industries; and (ii) medical uses in producing wound care dressings, oral delivery of proteins, construction of scaffolds in tissue engineering, and utilizing with the PTH-PSC Technology, in 3D Bioprinting and encapsulation.
Enquire about our Core Technology
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.